Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies?
Gilead Sciences agrees a $1.275 billion deal for HCXT-2001, an oral IL-23R inhibitor. Its IBD potential faces major clinical tests.
Pharma & Biotech
Pharma & Biotech
Gilead’s herpes candidate cut viral shedding by 98%. What will its latest IDWeek data reveal?
Gilead will present 28 studies at IDWeek 2026, covering Bixlenvo treatment outcomes, early real-world Yeztugo adoption and final Phase 1b findings for the investigational herpes medicine GS-1179. The programme examines how recently approved HIV treatments perform in practice while advancing a separate long-acting antiviral candidate.
Pharma & Biotech
Gilead is betting nearly $1.9bn on masked cancer drugs. What makes Vir’s technology different?
Vir Biotechnology and Gilead Sciences have agreed to develop three dual-masked T-cell engager programmes under a deal worth up to approximately $1.88 billion. The $90 million upfront package includes cash and equity, while most of the headline value depends on future development and commercial milestones.
Features & Analysis
Gilead is licensing once-yearly lenacapavir before Phase 3 results. Why take the manufacturing risk now?
Gilead Sciences has expanded royalty-free licensing agreements with six generic manufacturers to cover investigational once-yearly lenacapavir for HIV prevention while the Phase 3 PURPOSE 365 study is still underway. The decision deliberately moves manufacturing and access planning ahead of regulatory certainty, potentially shortening the years-long delay that has historically separated pharmaceutical innovation from broad availability
Pharma & Biotech
Gilead expands once-yearly lenacapavir access plan before pivotal HIV prevention data arrive
Gilead Sciences has expanded six royalty-free licenses to cover investigational once-yearly lenacapavir for HIV prevention, starting manufacturing preparations before the pivotal PURPOSE 365 study has delivered its results.
Pharma & Biotech
Gilead Sciences’ Bixlenvo turns up to 11 HIV pills into one, but who benefits most?
Gilead Sciences has secured U.S. Food and Drug Administration approval for Bixlenvo, a once-daily tablet combining bictegravir and lenacapavir for virologically suppressed adults with HIV, including patients whose resistance or treatment history has kept them on complex multi-tablet regimens.
Pharma & Biotech
Can FairJourney Bio’s reversible antibody switch solve IL-12’s decades-old toxicity problem?
FairJourney Bio engineers a tumor-conditional IL-12 switch designed to limit systemic exposure and localize cytokine activation in solid tumors.
Pharma & Biotech
Datroway EU approval expands first-line treatment options for metastatic triple-negative breast cancer
EU approval moves Datroway into first-line metastatic TNBC after TROPION-Breast02 showed survival gains, intensifying the TROP2 ADC race.
Pharma & Biotech
Atea eight-week hepatitis C regimen matches Epclusa in Phase 3 trial
Atea’s eight-week bemnifosbuvir and ruzasvir regimen matched 12-week Epclusa in a 905-patient Phase 3 hepatitis C trial.
Pharma & Biotech
ViiV Healthcare challenges three-drug HIV standard with positive Dovato VOGUE data
ViiV Healthcare’s VOGUE trial found Dovato non-inferior to Biktarvy at Week 48, sharpening the debate over two-drug first-line HIV care.